4//SEC Filing
Moran Kevin Patrick 4
Accession 0001209191-22-015155
CIK 0001347178other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 9:27 PM ET
Size
12.5 KB
Accession
0001209191-22-015155
Insider Transaction Report
Form 4
Moran Kevin Patrick
SVP, CFO & Treasurer
Transactions
- Sale
Common Stock
2022-03-02$11.28/sh−8,832$99,650→ 119,691 total - Award
Common Stock
2022-02-28+32,700→ 131,996 total - Sale
Common Stock
2022-03-01$11.19/sh−3,473$38,863→ 128,523 total - Award
Stock Option (Right to Buy)
2022-02-28+77,500→ 77,500 totalExercise: $11.36Exp: 2032-02-27→ Common Stock (77,500 underlying)
Holdings
- 635(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2023, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F2]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.18 to $11.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The option vests with respect to 25% of the underlying shares on February 28, 2023, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeother
Related Parties
1- filerCIK 0001806596
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 9:27 PM ET
- Size
- 12.5 KB